CHMP backs Joenja for APDS, putting EU approval within reach

Pharming said the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, has issued a positive opinion recommending marketing authorization for Joenja (leniolisib) for activated phosphoinositide 3-kinase delta syndrome, or APDS, in adults and children age 12 and older. The recommendation puts the oral PI3K-delta inhibitor one step away from a formal European Commission decision, which the company said is expected within about two months. If cleared, Joenja would become the first approved treatment for APDS in the EU, with authorization extending across all 27 member states plus Norway, Iceland, and Liechtenstein. (stocktitan.net)

Why it matters: For veterinary professionals tracking specialty therapeutics, this is another example of how precision medicines for rare immune disorders are moving from narrow trial settings into broader commercial markets. Joenja was already approved by the FDA in March 2023 as the first treatment for APDS in patients 12 and older, and Pharming has been working through EU manufacturing and quality questions even after regulators had signaled the drug’s clinical benefit and safety were positive. That kind of regulatory path matters because it shows how CMC issues, not just efficacy, can shape launch timing for rare-disease products. (fda.gov)

What to watch: The next milestone is the European Commission’s final decision, expected in Q2 2026, followed by country-level access and reimbursement discussions. (stocktitan.net)